Nothing Special   »   [go: up one dir, main page]

SG10201801281QA - Selective grp94 inhibitors and uses thereof - Google Patents

Selective grp94 inhibitors and uses thereof

Info

Publication number
SG10201801281QA
SG10201801281QA SG10201801281QA SG10201801281QA SG10201801281QA SG 10201801281Q A SG10201801281Q A SG 10201801281QA SG 10201801281Q A SG10201801281Q A SG 10201801281QA SG 10201801281Q A SG10201801281Q A SG 10201801281QA SG 10201801281Q A SG10201801281Q A SG 10201801281QA
Authority
SG
Singapore
Prior art keywords
grp94 inhibitors
selective grp94
selective
inhibitors
grp94
Prior art date
Application number
SG10201801281QA
Inventor
Gabriela Chiosis
Pengrong Yan
Pallav Patel
Hardik J Patel
Tony Taldone
Chenghua Yang
Weilin Sun
Stefan O Ochiana
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of SG10201801281QA publication Critical patent/SG10201801281QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B35/00—ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/60—In silico combinatorial chemistry
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/60—In silico combinatorial chemistry
    • G16C20/64—Screening of libraries

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Computing Systems (AREA)
  • Library & Information Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medical Informatics (AREA)
  • Diabetes (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
SG10201801281QA 2013-08-16 2014-08-15 Selective grp94 inhibitors and uses thereof SG10201801281QA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361866932P 2013-08-16 2013-08-16

Publications (1)

Publication Number Publication Date
SG10201801281QA true SG10201801281QA (en) 2018-04-27

Family

ID=52468819

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201801281QA SG10201801281QA (en) 2013-08-16 2014-08-15 Selective grp94 inhibitors and uses thereof
SG11201601542SA SG11201601542SA (en) 2013-08-16 2014-08-15 Selective grp94 inhibitors and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201601542SA SG11201601542SA (en) 2013-08-16 2014-08-15 Selective grp94 inhibitors and uses thereof

Country Status (17)

Country Link
US (3) US10421758B2 (en)
EP (1) EP3033338A4 (en)
JP (2) JP6539275B2 (en)
KR (1) KR102319582B1 (en)
CN (1) CN105899503B (en)
AU (2) AU2014306417C1 (en)
BR (1) BR112016003201A2 (en)
CA (1) CA2921571C (en)
EA (1) EA201690406A1 (en)
HK (1) HK1226063A1 (en)
IL (2) IL244251B (en)
MX (1) MX370664B (en)
PH (1) PH12016500511A1 (en)
SG (2) SG10201801281QA (en)
TW (1) TWI711618B (en)
WO (1) WO2015023976A2 (en)
ZA (1) ZA201601794B (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006084030A2 (en) 2005-02-01 2006-08-10 Sloan-Kettering Institute For Cancer Research Small-molecule hsp90 inhibitors
US9403828B2 (en) 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
ES2645095T3 (en) 2006-06-30 2017-12-04 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases through the inhibition of Hsp90
DK2486039T3 (en) 2009-10-07 2016-09-12 Sloan Kettering Inst For Cancer Res Purine derivatives that are useful as HSP90 INHIBITORS
EP2694506B1 (en) 2011-04-05 2017-09-20 Sloan-kettering Institute For Cancer Research Hsp90 inhibitors
WO2012138894A1 (en) 2011-04-05 2012-10-11 Sloan-Kettering Institute For Cancer Research Hsp90 inhibitors
ES2943498T3 (en) * 2013-08-05 2023-06-13 Twist Bioscience Corp de novo synthesized libraries
SG10201801281QA (en) * 2013-08-16 2018-04-27 Memorial Sloan Kettering Cancer Center Selective grp94 inhibitors and uses thereof
AU2014386214B2 (en) * 2013-12-23 2020-05-21 Memorial Sloan-Kettering Cancer Center Methods and reagents for radiolabeling
CN113521314A (en) * 2014-09-17 2021-10-22 纪念斯隆-凯特琳癌症中心 HSP 90-Targeted inflammation and infection imaging and treatment
BR112018006572A2 (en) 2015-10-05 2018-10-09 Memorial Sloan Kettering Cancer Center rational combination therapy for cancer treatment
CN108503643B (en) * 2017-02-28 2020-09-15 泉州易初生物医药科技有限公司 Process for the preparation of protease inhibitors
US11260132B2 (en) * 2017-03-16 2022-03-01 Children's Medical Center Corporation Engineered liposomes as cancer-targeted therapeutics
EP3737683A4 (en) * 2018-01-02 2022-01-05 Sanford Burnham Prebys Medical Discovery Institute Inhibitors of low molecular weight protein tyrosine phosphatase (lmptp) and uses thereof
US11774451B2 (en) * 2019-11-21 2023-10-03 The Board Of Trustees Of The Leland Stanford Junior University Molecular vibrational spectroscopic markers for detection of cancer
US20230220056A1 (en) * 2020-06-09 2023-07-13 Kookmin University Industry Academy Cooperation Foundation Antibody specifically binding to grp94 or antigen-binding fragment thereof, and uses thereof
KR20230000050A (en) 2021-06-24 2023-01-02 최현지 Fake Mask
CN113663078B (en) * 2021-06-28 2023-05-16 四川大学 Use of Grp94 inhibitors in the preparation of a medicament for the treatment of EGFR-driven cancers
KR20240012846A (en) 2022-07-21 2024-01-30 성균관대학교산학협력단 Novel HDAC6-selective inhibitors and uses thereof
CN115717144A (en) * 2022-08-25 2023-02-28 南通市肿瘤医院 Small interfering RNA for inhibiting HSP90B1 expression and application thereof in bladder cancer senescence
WO2024059745A2 (en) * 2022-09-15 2024-03-21 Bexson Biomedical, Inc. N-methyl-d-aspartate receptor (nmdar) antagonists and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0708772B1 (en) 1993-07-15 2000-08-23 Minnesota Mining And Manufacturing Company IMIDAZO [4,5-c]PYRIDIN-4-AMINES
JP4406205B2 (en) * 2000-11-02 2010-01-27 スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ Small molecule composition for binding to HSP90
WO2003037860A2 (en) 2001-10-30 2003-05-08 Conforma Therapeutics Corporation Purine analogs having hsp90-inhibiting activity
US20070129334A1 (en) * 2001-10-30 2007-06-07 Conforma Therapeutics Corporation Orally Active Purine-Based Inhibitors of Heat Shock Protein 90
EP1450784A4 (en) 2001-11-09 2005-02-09 Conforma Therapeutics Corp Hsp90-inhibiting zearalanol compounds and methods of producing and using same
US7148228B2 (en) 2003-09-18 2006-12-12 Conforma Therapeutics Corporation Pyrazolopyrimidines and related analogs as HSP90-inhibitors
US9403828B2 (en) 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
WO2006084030A2 (en) 2005-02-01 2006-08-10 Sloan-Kettering Institute For Cancer Research Small-molecule hsp90 inhibitors
JP2009521446A (en) 2005-12-22 2009-06-04 コンフォーマ・セラピューティクス・コーポレイション Orally active purine-based inhibitors of heat shock protein 90
NZ572600A (en) * 2006-05-12 2011-08-26 Myrexis Inc 6-Amino-purine derivatives for the treatment of cancer and fibrogenetic disorders
ES2645095T3 (en) 2006-06-30 2017-12-04 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases through the inhibition of Hsp90
AU2007305166A1 (en) * 2006-10-03 2008-04-10 University Of Southern California GRP78 as a predictor of responsiveness to therapeutic agents
JP5401329B2 (en) 2007-03-20 2014-01-29 キュリス，インコーポレイテッド Condensed aminopyridines as HSP90 inhibitors
CA2705579A1 (en) 2007-11-14 2009-05-22 Myriad Pharmaceuticals, Inc. Therapeutic compounds and their use in treating diseases and disorders
WO2010042500A2 (en) 2008-10-06 2010-04-15 Emory University Heat shock protein 90 inhibitors, methods of preparing same, and methods for their use
DK2486039T3 (en) 2009-10-07 2016-09-12 Sloan Kettering Inst For Cancer Res Purine derivatives that are useful as HSP90 INHIBITORS
WO2012138894A1 (en) 2011-04-05 2012-10-11 Sloan-Kettering Institute For Cancer Research Hsp90 inhibitors
EP2694506B1 (en) 2011-04-05 2017-09-20 Sloan-kettering Institute For Cancer Research Hsp90 inhibitors
US8685966B2 (en) * 2011-04-08 2014-04-01 University Of Kansas GRP94 inhibitors
AU2012262520A1 (en) 2011-05-27 2014-01-23 Cytocure Llc Methods, compositions, and kits for the treatment of cancer
MX347607B (en) 2011-07-08 2017-05-04 Sloan-Kettering Institute For Cancer Res Uses of labeled hsp90 inhibitors.
SG10201801281QA (en) * 2013-08-16 2018-04-27 Memorial Sloan Kettering Cancer Center Selective grp94 inhibitors and uses thereof

Also Published As

Publication number Publication date
US11267816B2 (en) 2022-03-08
MX2016002077A (en) 2016-07-21
ZA201601794B (en) 2019-09-25
AU2014306417B2 (en) 2019-01-17
US20200102312A1 (en) 2020-04-02
AU2014306417C1 (en) 2019-07-25
AU2019202669B2 (en) 2020-12-03
CA2921571A1 (en) 2015-02-19
PH12016500511A1 (en) 2016-06-13
BR112016003201A2 (en) 2017-11-21
EP3033338A2 (en) 2016-06-22
AU2019202669A1 (en) 2019-05-09
SG11201601542SA (en) 2016-04-28
JP2016533384A (en) 2016-10-27
IL267681B2 (en) 2023-03-01
US20230123747A1 (en) 2023-04-20
CN105899503A (en) 2016-08-24
TWI711618B (en) 2020-12-01
EP3033338A4 (en) 2017-06-14
IL244251B (en) 2019-07-31
IL267681A (en) 2019-08-29
IL267681B (en) 2022-11-01
WO2015023976A2 (en) 2015-02-19
KR20160043534A (en) 2016-04-21
JP6848009B2 (en) 2021-03-24
KR102319582B1 (en) 2021-11-04
HK1226063A1 (en) 2017-09-22
MX370664B (en) 2019-12-19
JP2019178147A (en) 2019-10-17
CN105899503B (en) 2020-08-18
US20160194328A1 (en) 2016-07-07
JP6539275B2 (en) 2019-07-03
US10421758B2 (en) 2019-09-24
IL244251A0 (en) 2016-04-21
TW201516047A (en) 2015-05-01
CA2921571C (en) 2022-04-05
WO2015023976A3 (en) 2015-04-23
AU2014306417A1 (en) 2016-03-17
EA201690406A1 (en) 2016-08-31

Similar Documents

Publication Publication Date Title
IL267681B (en) Selective grp94 inhibitors and uses thereof
HK1221660A1 (en) Acc inhibitors and uses thereof acc
HK1220355A1 (en) Mk2 inhibitors and uses thereof mk2
HK1221661A1 (en) Acc inhibitors and uses thereof acc
HK1221659A1 (en) Acc inhibitors and uses thereof acc
HK1219947A1 (en) Carm1 inhibitors and uses thereof carm1
HK1223089A1 (en) Kinase inhibitor and use thereof
HK1217410A1 (en) Erk inhibitors and uses thereof erk
HK1216859A1 (en) Irak inhibitors and uses thereof irak
HK1221662A1 (en) Acc inhibitors and uses thereof acc
SG11201505525UA (en) Bcl-2bcl-xl inhibitors and therapeutic methods using the same
IL244214B (en) Thienopiperidine derivative and use thereof
IL239762B (en) Selective nox-1 inhibitor peptides and uses thereof
EP2964225A4 (en) CaMKII INHIBITORS AND USES THEREOF
ZA201601880B (en) Hetero-transglycosylase and uses thereof
GB201304086D0 (en) Selective glycosidase inhibitors and uses thereof
GB201304084D0 (en) Selective glycosidase inhibitors and uses thereof
GB201304083D0 (en) Selective glycosidase inhibitors and uses thereof
GB201301393D0 (en) Kiddibidet and pottibidet